Related content

Compliance with osteoporosis drug therapy and risk of fracture

By Weycker D.   Macarios D.   Edelsberg J.   Oster G.  

Osteoporosis International, Vol. 18, Iss. 3, 2007-03 ,pp. : 271-277

Springer Publishing Company

Access to resources Recommend Favorite

Identification of Clinical Prognostic Factors in Patients with Unknown Primary Tumors Treated with a Platinum-Based Combination

By  

Oncology, Vol. 69, Iss. 2, 2005-09 ,pp. : 135-144

Karger

Access to resources Recommend Favorite

An Osteoporosis Clinical Pathway for the Medical Management of Patients with Low-Trauma Fracture

By Chevalley T.   Chevalley T.   Hoffmeyer P.   Bonjour J.-P.   Rizzoli R.  

Osteoporosis International, Vol. 13, Iss. 6, 2002-06 ,pp. : 450-455

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Features and Prognostic Factors in Severe Cutaneous Drug Reactions

By  

International Archives of Allergy and Immunology, Vol. 162, Iss. 4, 2013-10 ,pp. : 346-354

Karger

Access to resources Recommend Favorite

Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)

By Cooper C.   Jakob F.   Chinn C.   Martin-Mola E.   Fardellone P.   Adami S.   Thalassinos N.   Melo-Gomes J.   Torgerson D.   Gibson A.   Marin F.  

Osteoporosis International, Vol. 19, Iss. 4, 2008-04 ,pp. : 493-501

Springer Publishing Company

Access to resources Recommend Favorite